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Abstract
Pneumocystis jirovecii pneumonia (PCP) can affect various types of immunocompromised patients. We sought to evaluate the diagnostic
accuracy of (1 ﬁ 3)-b-D-glucan (BDG) for the diagnosis of PCP. We carried out a meta-analysis of relevant studies, identiﬁed through
PubMed and Scopus. Eligible studies were those that reported BDG diagnostic data in cases with documented PCP and controls with
other conditions. Cases of invasive fungal infections and healthy controls were excluded. We performed a bivariate meta-analysis of sen-
sitivity and speciﬁcity and constructed a hierarchical summary receiver operating characteristics (HSROC) curve. Fourteen studies were
included in the meta-analysis. BDG data were analysed for 357 PCP cases and 1723 controls. The average (95% conﬁdence interval)
sensitivity and speciﬁcity of BDG were 94.8% (90.8–97.1%) and 86.3% (81.7–89.9%), respectively. The positive and negative likelihood
ratios were 6.9 (5.1–9.3) and 0.06 (0.03–0.11), respectively. The area under the HSROC curve was 0.965 (0.945–0.978). Serum BDG
shows excellent sensitivity and very good speciﬁcity in the diagnosis of PCP. Still, in clinical practice the test results should be inter-
preted in the context of the underlying clinical characteristics of the individual patient.
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Introduction
Pneumocystis jirovecii pneumonia (PCP) is a common and
potentially serious opportunistic infection affecting patients
with immunosuppression due to various conditions. Such
conditions include infection with human immunodeﬁciency
virus (HIV), as well as haematological malignancies, solid
organ transplantation, solid tumours, and treatment with cer-
tain immunosuppressive agents [1].Although PCP often has a
characteristic clinical presentation with fever, dry cough,
dyspnoea, hypoxia and diffuse ground glass opacities in the
chest X-ray, the differential diagnosis of pulmonary inﬁltrates
in patients with immunosuppression is broad [2,3].
Establishing the diagnosis of PCP requires identiﬁcation of
this fungal pathogen using various methods in respiratory
tract samples from patients with a compatible clinical presen-
tation. Such samples include induced sputum and bronchoal-
veolar lavage ﬂuid [3].However, many patients are not able
to provide an appropriate sputum specimen, while bronchos-
copy might not be readily available or safe to perform in
some of these patients [4]. The diagnosis of PCP can be par-
ticularly problematic for patients with immunosuppression
related to conditions other than HIV infection [5]. These
patients typically have PCP that progresses rapidly, which
does not allow for delay in the institution of speciﬁc
treatment. They also have a relatively lower burden of the
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pathogen in respiratory tract secretions, which is associated
with lower diagnostic yield [6]. Additionally, the diagnosis
can be obscured in patients who receive PCP prophylaxis,
owing to altered clinical course of PCP and lower counts of
the organism in respiratory specimens [7].
In routine clinical practice, some patients with suspected
PCP will receive empirical treatment, mainly with trimetho-
prim-sulphamethoxazole. This could be associated with
unnecessary drug toxicity (e.g. hypersensitivity reactions in
HIV-infected patients or myelosuppression in haematological
patients) [8]. An incorrect clinical diagnosis of PCP could
also be associated with failure to detect and treat other
potentially serious conditions [3].
Some serum or plasma biomarkers have been studied with
the aim of improving the diagnosis of PCP [9]. (1 ﬁ 3)-b-D-
glucan (BDG) is a candidate such marker. It is an element of
the cyst wall of P. jirovecii (and of the cell wall of most other
fungi), that can trigger various host inﬂammatory responses
[10]. We sought to evaluate the diagnostic accuracy of BDG
for the diagnosis of PCP with a meta-analysis of relevant
studies.
Methods
Literature search
We searched in PubMed and Scopus bibliographical databas-
es, up to August 2011, to identify studies that have evaluated
the diagnostic value of serum or plasma BDG between
patients with PCP and controls without PCP. The search
term used for both the above databases was ‘glucan AND
pneumocystis’. We additionally searched in the reference lists
of relevant articles to identify eligible for inclusion studies.
Study selection criteria
For a study to be eligible for inclusion in the meta-analysis,
the diagnosis of PCP had to be made in patients who had rel-
evant clinical manifestations with detection of the pathogen in
sputum or bronchoalveolar lavage ﬂuid, either by microscopy
using conventional or immunoﬂuorescent stains for P. jirovecii
or with polymerase chain reaction; alternatively, the detec-
tion of P. jirovecii could have been achieved by histopathology
in lung biopsy or autopsy specimens. Infants with primary P. ji-
rovecii lung infection were also included as cases. Cases diag-
nosed with probable PCP based on clinical and radiological
ﬁndings alone were excluded. Controls needed to be patients
with diagnoses other than PCP (such as patients with other
respiratory infections/diseases and patients with conditions
rendering them at risk for PCP or an invasive fungal infec-
tion). Patients with documented invasive fungal infections and
healthy controls were excluded. If a study did not report spe-
ciﬁc data to allow for the exclusion of the above two patient
groups, it was included only if the patients in these groups
constituted <25% of the total control group. Studies that pro-
vided BDG diagnostic data that could not make mathematical
sense according to known mathematical formulas were
excluded. Articles written in languages other than English,
Spanish, French, German or Italian were also excluded.
Data extraction
From each of the included studies we extracted data on
study design, the characteristics of the patient groups that
were of interest to our meta-analysis, the criteria for the
diagnosis of PCP, the strategy of BDG sampling, the criteria
used for the deﬁnition of a positive test result, the method-
ology of BDG testing, and whether or not antimicrobial pro-
phylaxis for PCP had been administered. We also extracted
BDG diagnostic data, including the test cut-off level and the
number of patients with true/false positive and true/false neg-
ative BDG results. If the actual numbers for any of the above
patient categories were not directly provided, we calculated
these numbers from data on sensitivity/speciﬁcity or positive/
Articles retrieved from 
PubMed (n = 141)
Articles selected for further 
evaluation after first screen 
(n = 36)
Articles excluded for specific 
reasons (n = 25):
•No control group (n = 13)
•PCP diagnostic criteria not 
appropriate (n = 5)
•Data for IFIs only (n = 3)
•No specific BDG diagnostic 
data provided (n = 2)
•Case report (n = 1)
•Data for less than 3 PCP 
cases (n = 1)
Included studies (n = 11)
FIG. 1. Flow diagram for the process of selection of articles for
inclusion in the meta-analysis from PubMed search results.
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negative predictive value using common mathematical formu-
las. If diagnostic data for more than one cut-off level were
reported, we included data on the cut-off level that was clo-
ser to the one approved for each BDG assay.
Data analysis
We carried out a meta-analysis of the diagnostic accuracy of
BDG using a statistical model of bivariate meta-analysis of
sensitivity and speciﬁcity [11,12]. We also calculated the
positive/negative likelihood ratio (the ratio of the probabili-
ties that the test will be positive/negative in cases with PCP
vs. those without PCP) and the diagnostic odds ratio (which
can be expressed as the positive likelihood ratio/negative
likelihood ratio) [13]. We constructed a hierarchical sum-
mary receiver operating characteristics (HSROC) curve [11].
We assessed the presence of between-studies statistical het-
erogeneity using the chi-squared test [14]. A p value <0.1
for the chi-squared test indicated the presence of statistical
heterogeneity. We also assessed the presence of between-
studies heterogeneity by visual inspection of the ROC plane
[15]. For all analyses performed, we used the midas module
in Stata software v. 10 [16].
Results
Our bibliographical search in PubMed and Scopus yielded
initially 141 and 206 articles, respectively. Fourteen studies
were identiﬁed as eligible for inclusion in the meta-analysis
[17–30]. Speciﬁcally, 11 eligible for inclusion studies were
identiﬁed between the PubMed search results (Fig. 1)
[17–21,23,24,26–30]. Four additional articles were selected
for further evaluation among the Scopus search results and
two of them were eligible for inclusion [17,22]. One
additional study was included after hand-searching the biblio-
graphical references of relevant articles [25].
Characteristics of the included studies
Table 1 presents the main characteristics of the included stu-
dies, as well as the BDG diagnostic data extracted from each
of the studies and analyzed. The year of publication of the
included studies was 2006 or later, except for two studies
that were published before 2000 [29,30].The study design
was retrospective for all included studies, except for two
prospective studies [17,19]. The PCP cases evaluated con-
sisted exclusively of HIV-infected patients in two studies
[24,30], of mixed HIV-infected patients and patients with
other types of immunosuppression in eight studies
[17,18,20,21,23,26,27,29], and of non-HIV immunosuppressed
patients in two studies [19,28], while relevant data were not
clearly reported in the remaining two studies [22,25]. The
specimen used for the detection of P. jirovecii was bronchoal-
veolar lavage ﬂuid in eight of the included studies [17,19–
21,23,24,26,27], bronchoalveolar lavage ﬂuid or other respi-
ratory specimens in four studies [18,22,28,30], and autopsy
specimens in the remaining two studies [25,29].
Seven of the included studies used the Fungitell assay
(Associates of Cape Cod Inc., East Falmouth, MA, USA) for
the measurement of BDG [17–22,26]. Three studies used
the Fungitec G-test MK assay and two additional studies
used the G-test assay (both are developed by Seikagaku
Corp, Tokyo, Japan) [23–25,29,30]. Two studies used the b-
glucan test Wako (Wako Pure Chemical Industries Ltd,
Osaka, Japan) [27,29]. One of the above studies evaluated
both the Fungitec G test MK and the b-glucan test Wako
[29]. We included diagnostic data referring to the former
assay in the meta-analysis. Finally, the remaining study did
not specify the BDG assay method used [28]. In all of the
included studies, BDG was measured in serum samples,
except for one that used plasma [29]. The deﬁnition of a
positive BDG test was based on a single speciﬁed positive
test result in 12 of the included studies, while relevant data
were not accurately reported in the remaining two studies
[28,29].
Diagnostic accuracy of BDG
The 14 analysed studies provided, in total, BDG diagnostic
data for 357 patients with PCP and 1723 controls with other
conditions. The bivariate meta-analysis resulted in an average
sensitivity of BDG for the diagnosis of PCP of 94.8% (95%
conﬁdence interval (CI), 90.8–97.1%) and an average speciﬁc-
ity of 86.3% (95% CI, 81.7–89.9%) (Fig. 2). Additionally,
the average positive likelihood ratio for BDG was 6.9 (95%
CI, 5.1–9.3) and the negative likelihood ratio was 0.06 (95%
CI, 0.03–0.11). The diagnostic odds ratio was 113.7 (95% CI,
55.7– 232.3). The area under the HSROC curve was 0.965
(95% CI, 0.945– 0.978) (Fig. 3). The p value for the chi-
squared test for heterogeneity was 0.31. The visual inspec-
tion of the ROC plane (Fig. 3) showed that the summary
points for two studies lie clearly out of the 95% prediction
ellipse (contour), which is indicative of between-studies het-
erogeneity [28,30]. These two outliers consisted of a study
that did not speciﬁcally describe the method used [28] and
the oldest of the included studies [30].
Discussion
In this meta-analysis, serum or plasma BDG had an excellent
sensitivity and very good speciﬁcity for the diagnosis of docu-
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mented PCP in patients with HIV infection, haematological
malignancies or other underlying risk factors. The negative
likelihood ratio of BDG was very low, indicating that a nega-
tive test is much less likely to be observed in patients with
PCP compared with patients without PCP. The positive like-
lihood ratio was moderately high (7.1), reﬂecting the fact
that BDG might be falsely positive in some patients without
PCP. The area under the HSROC curve was more than 0.90,
indicating an overall very high diagnostic accuracy of the test.
The presence of PCP was documented with polymerase
chain reaction or microscopic examination of respiratory
tract specimens (bronchoalveolar lavage ﬂuid or sputum) or
with histological examination of autopsy specimens. How-
ever, the analysed studies differed in many of their character-
istics, including the study design, the characteristics of the
study population, the reference diagnostic method, and the
type of the BDG assay used.
The sensitivity of BDG (94.7%) for the diagnosis of PCP
found in this meta-analysis appears to be greater than the
sensitivity of BDG for the diagnosis of invasive fungal infec-
tions (mainly, invasive aspergillosis or systemic candidiasis)
found in another meta-analysis (average sensitivity of 76.8%)
[31]. Very high sensitivity of BDG in different groups of
patients with PCP has been noted in several studies that
have not included a control group and, therefore, they were
not eligible for inclusion in this meta-analysis. For example,
one study has found that serum or plasma BDG was positive
in 33/34 (97.1%) cases of PCP in patients with acquired
immunodeﬁciency syndrome (AIDS) [32]. Another study has
found that serum BDG was positive in 15/16 (93.8%) patients
with PCP related to various underlying conditions [33]. A
third study has reported that BDG was positive in 13/15
(86.7%) patients with PCP and underlying connective tissue
diseases [34]. In a larger study that retrospectively evaluated
a clinical-trial cohort, the sensitivity of BDG for the detec-
tion of 173 cases with conﬁrmed or probable PCP was 92%
[35].
The high sensitivity of BDG in the diagnosis of PCP sug-
gests that a negative serum BDG result could reasonably
exclude PCP in patients with a low or moderate pretest
probability for the disease. For example, if the pretest proba-
bility of PCP (which can be estimated subjectively by clinical
judgement or can be considered equal to the prevalence of
the disease in a speciﬁc patient population) is 30%, the prob-
ability that PCP will be present after a negative BDG test will
be <5%, even if the lowest bound of the 95% interval for
sensitivity (90.2%) is used in the calculation.
The speciﬁcity of BDG found in this meta-analysis (86.3%)
appears similar to the speciﬁcity of BDG in patients at risk
of invasive fungal infections found in another relevant meta-T
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analysis (average sensitivity of 85.3%) [31]. In clinical practice,
care must be taken when evaluating BDG in patients with
factors that could account for a false positive BDG result,
such as haemodialysis through cellulose membranes, applica-
tion of certain types of gauzes on mucosal or serosal
surfaces, administration of blood products produced through
cellulose ﬁlters, Gram-negative endotoxinemia, use of certain
antimicrobial agents, renal failure, or severe mucositis [36–
38]. One or more of the above characteristics are likely to
be present in certain patient groups, such as critically ill
patients, where the use of the BDG test warrants caution
[39].
Most importantly, the presence of an invasive fungal infec-
tion as the cause of a positive BDG test, instead of PCP,
must be carefully considered for every individual patient. For
example, in patients with HIV infection, an elevated BDG
could represent underlying histoplasmosis, crytpococcosis
or, even probably oesophageal candidiasis, rather than PCP
[35]. Likewise, in patients with haematological malignancies,
invasive aspergillosis or systemic candidiasis are common
causes of an elevated BDG [40]. In our meta-analysis, we
excluded cases with invasive fungal infections from the con-
trol group, because the aim was to evaluate the diagnostic
performance of the test against well-deﬁned reference
patient groups. The combined evaluation of BDG with spe-
ciﬁc diagnostic tests for suspected invasive fungal infections
(e.g. serum fungal antigens or galactomannan) has been pro-
posed as a diagnostic strategy to overcome the above limita-
tion [35,41].
Some studies have found very high BDG serum values in
the majority of patients with PCP [42]. This has been mostly
observed for HIV-infected patients, in whom the counts of
the infecting organisms can be particularly high, but also for
patients with other types of immunosuppression, such as
haematological malignancies [21–23,26]. The above ﬁndings,
if conﬁrmed, might suggest that the optimal cut-off level of
BDG for the diagnosis of PCP could be different to the one
used for invasive fungal infections. The HSROC curve we
FIG. 2. Forest plot of the bivariate meta-analysis of the sensitivity and speciﬁcity of (1 ﬁ 3)-b-D-glucan for the diagnosis of Pneumocystis jirovecii
pneumonia. The circles in squares and horizontal lines represent the point estimate and 95% conﬁdence interval, respectively, for each included
study; the dotted line represents the average point estimate; the diamond shape represents the 95% conﬁdence interval of the average estimate.
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created shows the expected variation in sensitivity and speci-
ﬁcity with the variation in the cut-off level. If the aim is to
increase the speciﬁcity of the test, a slightly higher cut-off
level than the one used for the diagnosis of invasive fungal
infections could potentially provide higher speciﬁcity without
unacceptable loss in sensitivity [21].
An important consideration in the evaluation of the utility
of any diagnostic test is the accuracy of the reference stan-
dard. The sensitivity of the routine diagnostic methods for
PCP is not optimal, particularly for certain patient groups
[43]. For example, PCP can be strongly suspected clinically
and radiographically or on the basis of response to empirical
therapy, but the pathogen might be detected with usual
microscopic methods. Some such cases in which BDG has
been found positive have been reported, suggesting that
BDG testing could augment our ability to diagnose PCP
[22,44]. Furthermore, the detection of P. jirovecii DNA in
sputum samples from immunosuppressed patients with pul-
monary inﬁltrates can sometimes merely represent coloniza-
tion [45]. Serum BDG could potentially be of value in
differentiating between colonization and infection in such
cases [46].
Although our meta-analysis shows very high diagnostic
accuracy of BDG for PCP, certain limitations should be
considered. The main one is that almost all of the included
studies were retrospective in nature. Moreover, speciﬁc and
clinically relevant diagnostic strategies of serial BDG measure-
ments in high-risk patients for PCP were not evaluated in the
included studies. A large prospective study of high methodo-
logical quality would be useful to corroborate the ﬁndings of
this meta-analysis. Notably, a study that evaluated a twice-
weekly BDG screening strategy for early diagnosis of invasive
fungal infections in patients with haematological malignancies
has found a high rate of false-positive test results [40].
Secondly, the included studies differed in many of their
characteristics, which is commonly observed in diagnostic
test accuracy reviews. It cannot be excluded that the accu-
racy of BDG testing for the diagnosis of PCP may differ
between different patient groups. For example, haematologi-
cal neutropenic patients are at high risk of developing inva-
sive fungal infections, which can be the cause of a positive
BDG result. The role of BDG testing in patients receiving
PCP prophylaxis has also not been adequately evaluated.
Finally, different BDG assays were used in the studies analy-
sed, with potential differences in their diagnostic perfor-
mance, although there are many similarities between the
Fungitell and the Fungitec assays, which were used in the
majority of the included studies [25,47]. It should be men-
tioned, however, that the methods we used for this meta-
analysis are valid in the presence of heterogeneity in the
characteristics of the analysed studies, including explicit or
implicit differences in the diagnostic threshold [48].
In conclusion, this meta-analysis shows a very high accuracy
of the serum or plasma BDG assay for the diagnosis of PCP in
patients with documented PCP vs. those with other condi-
tions. The very high sensitivity of BDG suggests that a negative
result in patients without a high pretest probability of PCP
should lead to the consideration of an alternative diagnosis. In
addition, a positive BDG result can be a strong indicator for
the presence of PCP in patients with compatible clinical and
radiological ﬁndings. In patients with low pretest probability
for PCP, however, a positive BDG should be interpreted in
the context of the presence or not of other factors that can
increase BDG. An appropriately designed prospective study
would be useful to further corroborate the above ﬁndings.
Certain factors regarding the optimal application of BDG test-
ing for the diagnosis of PCP warrant further evaluation.
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FIG. 3. Summary hierarchical receiver operating characteristics
(HSROC) curve of the sensitivity vs. speciﬁcity of (1 ﬁ 3)-b-D-glu-
can for the diagnosis of Pneumocystis jirovecii pneumonia. The straight
line represents the HSROC curve; the shaded diamond shape repre-
sents the point of the curve that corresponds to the average point
estimates of sensitivity and speciﬁcity; the dashed line represents the
95% conﬁdence area for this point; the numbered circles represent
the data from each of the included studies; and the dotted line (the
95% prediction contour) represents the 95% conﬁdence area in
which a new relevant study will be located.
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